Direkt zum InhaltDirekt zur SucheDirekt zur Navigation
▼ Zielgruppen ▼

Humboldt-Universität zu Berlin - IRI Life Sciences

Humboldt-Universität zu Berlin | IRI Life Sciences | Events | Colloquium | Cell Communication | IRI-Schering Colloquium - Nassos Typas: "Drugs, bugs and chemical genomics"

IRI-Schering Colloquium - Nassos Typas: "Drugs, bugs and chemical genomics"

EMBL Heidelberg
What
  • Cell Communication
  • Colloquium
When Feb 01, 2018 from 04:00 PM to 05:30 PM (Europe/Vienna / UTC100) iCal
Where IRI Life Sciences, Philippstr. 13, Bld. 18, 3rd Floor
Contact Name

coll.pngSchering

 

 

If you like to meet our speaker for a personal discission, please contact stefanie.scharf@iri-lifesciences.de

 

Abstract:

Systematic and quantitative profiling of functional interactions at a genome-wide level provides unique insights into cellular behaviors and the underlying network architecture. We have developed new tools and strategies for chemical genetics approaches bacteria, and applied it to E. coli and Salmonella Typhimurium. Thereby, we identified robust quantitative phenotypes for almost every E. coli gene, linked > 800 E. coli genes of unknown function to mapped processes - providing a strong basis for future mechanistic dissection of their role, determined conserved and rewired functional modules between the two organisms. We also use this information to predict phenotypes of natural E. coli populations, based on sequence variance. At a second level, we profiled ~ 3,000 combinations of different antibiotics, selected human-targeted drugs and food additives in Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa, at different drug doses. Our results illuminate key principles of drug-drug interactions and their underlying cellular networks, provide a framework for assessing the conservation of drug interactions across organisms, emphasize the promise that non-antibiotic drugs hold as adjuvants, and offer a new path for design of narrow spectrum therapies. Finally, as part of an EMBL ongoing collaboration, I will present new insights into the effects of medication in human gut microbiome.